Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Glaukos Corp    GKOS

GLAUKOS CORP (GKOS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/14/2018 02/15/2018 02/16/2018 02/20/2018 02/21/2018 Date
31.01(c) 31.28(c) 31.07(c) 31.23(c) 31.68 Last
393 025 274 794 180 479 355 124 84 303 Volume
+4.45% +0.87% -0.67% +0.51% +1.44% Change
More quotes
Financials ($)
Sales 2017 158 M
EBIT 2017 0,61 M
Net income 2017 -1,47 M
Finance 2017 10,0 M
Yield 2017 -
Sales 2018 170 M
EBIT 2018 1,95 M
Net income 2018 -1,44 M
Finance 2018 37,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 846,59
EV / Sales2017 6,72x
EV / Sales2018 6,08x
Capitalization 1 074 M
More Financials
Company
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of products and procedures designed to transform the treatment of glaucoma.Its micro invasive glaucoma surgery procedures are designed to reduce intraocular eye pressure by improving... 
More about the company
Surperformance© ratings of Glaukos Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAUKOS CORP
02/08GLAUKOS : iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medicati..
BU
02/07GLAUKOS CORPORATION : to Release Fourth Quarter and Full Year 2017 Financial Res..
BU
01/27GLAUKOS : Glaucoma Research Foundation to Host the 7th Annual Glaucoma 360, a Th..
AQ
01/11GLAUKOS CORPORATION : s iDose Travoprost Achieves Sustained IOP Reduction and Fa..
AQ
01/10GLAUKOS CORPORATION (NYSE : GKOS) Files An 8-K Regulation FD Disclosure
AQ
01/10GLAUKOS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
01/10GLAUKOS CORPORATION : ’s iDose™ Travoprost Achieves Sustained IOP Re..
BU
01/04GLAUKOS : Submits IDE Application to FDA to Study iStent infinite Trabecular Mic..
AQ
01/03GLAUKOS : Submits IDE Application to FDA to Study iStent infinite™ Trabecu..
BU
2017GLAUKOS CORP : Wired News - Glaukos Submits Pre-Market Approval Application to F..
AC
More news
Sector news : Medical Devices & Implants
12:14aOMAR ISHRAK : Pay if It Works -- WSJ
DJ
02/20MEDTRONIC : U.S. Revenue Drops -- Earnings Review
DJ
02/20MEDTRONIC MOVES TO A NEW HEALTH-CARE : Pay Only if It Works
DJ
02/15STRYKER : U.S. Regulators Extend Window for Critical Stroke Treatment
DJ
02/15STRAUMANN : margin outlook takes shine off revenue surge
RE
More sector news : Medical Devices & Implants
Latest Tweets
02/20Glaukos Corp $GKOS Given Average Rating of “Hold” by Analysts  
02/16$GKOS - Zacks Investment Research Downgrades Glaukos #GKOS to Sell  
02/13#CPA #CFP #PFS link: Bill Restores Tax Exemption for Advance Refunding Bonds .. 
02/08Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medicat.. 
02/08Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medicat.. 
More tweets
Qtime:214
News from SeekingAlpha
01/10Glaukos' iDose Travoprost demonstrates sustained lowering of IOP in mid-stage.. 
2017Glaukos on go to start pivotal study of next-generation iStent; shares up 1% 
2017Glaukos with quick dive on report of reduced reimbursements 
2017Glaukos awarded new U.S. patent covering MIGS device 
2017HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
Chart GLAUKOS CORP
Duration : Period :
Glaukos Corp Technical Analysis Chart | GKOS | US3773221029 | 4-Traders
Technical analysis trends GLAUKOS CORP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 42,4 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Thomas William Burns President, Chief Executive Officer & Director
William J. Link Chairman
Chris M. Calcaterra Chief Operating Officer
Joseph E. Gilliam CFO & Senior VP-Corporate Development
Jeffrey Mark Wells Senior VP-Regulatory, Quality & Clinical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
GLAUKOS CORP20.90%1 074
STRYKER CORPORATION0.90%59 894
SMITH & NEPHEW-1.16%15 553
JAPAN LIFELINE CO., LTD.48.41%2 945
WRIGHT MEDICAL GROUP NV-7.61%2 107
OSSTEM IMPLANT CO LTD--.--%671